MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Diagnostic Demography of the Ataxia Unit at UNIFESP: 12 years experience

    B. Massuyama, M. Gama, F. Abrantes, F. Filho, F. Maggi, R. Salomao, J. Freitas, S. Costa, I. Raslan, G. Diaferia, P. Matos, V. Ciarlariello, C. Jaques, M. Moraes, J. Pedroso, O. Barsottini (Sao Paulo, Brazil)

    Objective: To describe the historical demography of diagnosed ataxia cases made in a tertiary neurological outpatient clinic in Sao Paulo, Brazil. Background: The term ataxia…
  • MDS Virtual Congress 2020

    Disconnected brain in functional movement disorders with anxious & depressive symptoms

    F. Růžička, R. Jech, K. Mueller, M. Slovák, Z. Forejtová, T. Serranová (Prague, Czech Republic)

    Objective: The aim of this study was to investigate the functional brain network abnormalities underlying depression and/or anxiety symptoms (DEP/ANX) in functional movement disorders (FMD).…
  • MDS Virtual Congress 2020

    First Scientific Description of the Hepato-Lenticular Degeneration

    D. Labunskiy, S. Kiryukhina, N. Kolmykova (Saransk, Russian Federation)

    Objective: Hepato-Lenticular Degeneration (HLD) first described by German pathologist Friedrich Theodor von Frerichs in 1854, but in the West it called Wilson's Disease. In Russia…
  • MDS Virtual Congress 2020

    VMAT 2 inhibitor and Antipsychotic use in Individuals with Huntington’s Disease

    E. Furr Stimming, L. Zhu, N. Pessoa Rocha (Houston, TX, USA)

    Objective: To retrospectively investigate whether the concomitant use of VMAT2 inhibitors and antipsychotics in individuals with Huntington's disease (HD) is associated with an increased occurrence…
  • MDS Virtual Congress 2020

    Translatable biomarkers in gene therapy for Huntington’s Disease: learnings from pre-clinical studies

    A. Valles, M. Evers, A. Stam, M. Sogorb-Gonzales, C. Brouwers, C. Vendrell, S. Acar-Broekmans, V. Fodale, A. Bresciani, R. Nieuwland, Z. Ellederova, J. Motlik, M. de Haan, B. Leavitt, S. van Deventer, P. Konstantinova (Amsterdam, Netherlands)

    Objective: We have developed AAV5-miHTT, a recombinant AAV-based gene therapy expressing an engineered microRNA that specifically binds to HTT exon1, resulting in lowering of both…
  • MDS Virtual Congress 2020

    Progression of cortical thinning and neuropsychological decline in isolated Rapid Eye Movement sleep behavior disorder

    A. Inguanzo, B. Segura, A. Campabadal, A. Abos, C. Uribe, M. Serradell, C. Gaig, J. Santamaria, Y. Compta, C. Junque, A. Iranzo (Barcelona, Spain)

    Objective: We aimed to investigate the progression over time of cortical thickness and cognitive functions in isolated REM-sleep behaviour disorder (IRBD) compared to healthy controls (HC).…
  • MDS Virtual Congress 2020

    hUC-MSCs ameliorated CUMS-induced depression by modulating complement C3 signaling-mediated microglial polarization during astrocyte-microglia crosstalk

    J. Li, H.L Wang, M.W Wang (Shijiazhuang, China)

    Objective: To demonstrate whether hUC-MSCs can benefit depressive-like behavior by altering C3/C3a-C3aR signaling to impact microglia polarization in the CUMS model. Background: Major depressive disorder (MDD) has been…
  • MDS Virtual Congress 2020

    MR Conditional Labeling for DBS – Basic Physics for the Non-Specialist

    M. Conroy, S. Falowski, D. Sayed, L. Poree, K. Chakravarthy, R. Banerjee, J. Kramer (Minneapolis, MN, USA)

    Objective: A non-technical overview of the physics behind MR Conditional labeling for DBS devices and the implications for diagnostic imaging. Background: MRI is the recommended…
  • MDS Virtual Congress 2020

    An Analysis of Health Care Utilization in Functional Movement Disorders: Does Diagnosis Make a Difference?

    K. Kyle, A. Wu, F. Agosta (Los Angeles, CA, USA)

    Objective: To investigate the impact of diagnosis on health care utilization (HCU) in the functional movement disorders (FMD) population. Background: FMD patients are considered to…
  • « Previous Page
  • 1
  • …
  • 147
  • 148
  • 149

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley